Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)

Roll, Petra and Ostermeier, Eva and Haubitz, Marion and Lovric, Svjetlana and Unger, Leonore and Holle, Julia and Koetter, Ina and Henes, Joerg C. and Bergner, Raoul and Rubbert-Roth, Andrea and Specker, Christof and Schulze-Koops, Hendrik and Mueller-Ladner, Ulf and Fleck, Martin and Burmester, Gerd-Ruediger and Hiepe, Falk and Heitmann, Stefan and Aringer, Martin and Fischer-Betz, Rebecca and Doerner, Thomas and Tony, Hans-Peter (2012) Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). JOURNAL OF RHEUMATOLOGY, 39 (11). pp. 2153-2156. ISSN 0315-162X,

Full text not available from this repository. (Request a copy)

Abstract

Objective. Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV. Methods. Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry. Results. In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least I cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders. Conclusion. RTX was well tolerated with good clinical efficacy in patients with refractory AAV. (First Release Sept 15 2012; J Rheumatol 2012;39:2153-6; doi:10.3899/jrheum.120482)

Item Type: Article
Uncontrolled Keywords: WEGENERS-GRANULOMATOSIS; THERAPY; CYCLOPHOSPHAMIDE; MANIFESTATIONS; EXPERIENCE; DEPLETION; RITUXIMAB; EFFICACY; SAFETY; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIDES
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Dr. Gernot Deinzer
Date Deposited: 05 May 2020 05:01
Last Modified: 05 May 2020 05:01
URI: https://pred.uni-regensburg.de/id/eprint/17864

Actions (login required)

View Item View Item